Unveiling the nanoworld of antimicrobial resistance: integrating nature and nanotechnology
Acute Bacterial Skin And Skin-Structure Infection (ABSSSI) Market: Insights Into Epidemiology, Treatments, And Key CompaniesMicuRx, Basilea Pharmaceuticals, AbbVie, Cubist ...
"Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market"
As per secondary analysis, ABSSSI accounted for almost 870,000 hospital admissions in the United States in 2004 which represents an increase of almost 30% in the incidence of this diagnosis over a 4-year period.
Emerging therapies for acute bacterial skin and skin-structure infections (ABSSSI), including DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others, are anticipated to drive growth in the ABSSSI market in the coming years.
DelveInsight has published a new report titled "Acute Bacterial Skin and Skin-Structure Infection – Market Insights, Epidemiology, and Market Forecast–2034", providing a comprehensive analysis of the condition, including historical and projected epidemiology and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Acute bacterial skin and skin-structure infection market report @ https://www.Delveinsight.Com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?Utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Acute bacterial skin and skin-structure infection Market Report:
In April 2024, the U.S. FDA approved Zevtera (ceftobiprole medocaril sodium), a broad-spectrum cephalosporin antibiotic, for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) in adults. This approval provides healthcare providers with an additional option for addressing serious infections caused by a range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Zevtera received priority review, fast track, and qualified infectious disease product designations from the FDA, highlighting its potential to meet unmet medical needs in ABSSSI treatment. Approval was based on data from four randomized controlled trials, in which 91.3% of patients receiving Zevtera achieved an early clinical response (within 48–72 hours), compared with 88.1% in the comparator group.
Earlier, in July 2021, the FDA approved AbbVie's DALVANCE (dalbavancin) for treating ABSSSI in pediatric patients, including newborns. MRSA-related hospitalizations were highest among the elderly, with 360.8 stays per 100,000 patients over 65 years, over three times higher than other age groups. Rates for other groups included 114.7 per 100,000 infants, 19.2 per 100,000 children aged 1–17, 58.1 per 100,000 adults aged 18–44, and 111.5 per 100,000 adults aged 45–64.
Historical data indicate that ABSSSI accounted for nearly 870,000 hospital admissions in the U.S. In 2004, reflecting a ~30% increase over four years. Between 2005 and 2011, adult ABSSSI admissions increased by 17.3%, with patients predominantly male (50.8%), white (60.3%), and a mean age of 55.7 years.
The ABSSSI market is expected to evolve with new treatment options, regulatory changes, and shifts in healthcare spending, potentially increasing competition among pharmaceutical companies and improving patient outcomes. Key players, including DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others, are actively developing new therapies. Promising treatments under investigation, such as DALVANCE, ORBACTIV, MRX-4, and Zevtera, are expected to further enhance the ABSSSI treatment landscape.
Acute bacterial skin and skin-structure infection Overview
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) refers to a group of bacterial infections that affect the skin and underlying soft tissues. The severity of these infections can vary, typically presenting with symptoms such as redness, warmth, localized swelling, and sometimes pus formation. The most common causative pathogens include Staphylococcus aureus (including MRSA strains), Streptococcus pyogenes, as well as other Gram-positive and Gram-negative bacteria.
Acute bacterial skin and skin-structure infection Market Outlook
Treatment of ABSSSI aims to relieve symptoms, enhance quality of life, halt disease progression, and prevent recurrence. Initial therapy typically involves oral antibiotics targeting streptococcal infections, particularly in cases of cellulitis. However, the increasing prevalence of MRSA has necessitated adjustments in treatment strategies. For mild, non-purulent infections, commonly used antibiotics include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin.
For MRSA-related infections, both oral and intravenous options are available, including sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. These MRSA-specific antibiotics are particularly important when infections result from penetrating trauma, such as intravenous drug use. Selection and duration of therapy are guided by infection severity, patient characteristics, and patterns of antibiotic resistance.
Newer antibiotics, including DALVANCE, ORBACTIV, and SIVEXTRO, have been developed to target MRSA, offering long half-lives that allow less frequent dosing and improve patient adherence. Oritavancin, a lipoglycopeptide with a novel mechanism of action, provides an additional option with single-dose administration, broad-spectrum coverage—including MRSA—and the potential to simplify treatment and enhance compliance.
Ongoing research continues to advance ABSSSI management, aiming to improve patient outcomes and reduce healthcare burdens. According to DelveInsight, the ABSSSI market is expected to undergo significant evolution between 2020 and 2034.
Discover how the Acute bacterial skin and skin-structure infection market is rising in the coming years
Acute Bacterial Skin and Skin-Structure Infection Marketed Drugs
Acute bacterial skin and skin-structure infection Emerging Drugs
Scope of the Acute bacterial skin and skin-structure infection Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute bacterial skin and skin-structure infection Companies: MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics, and others
Key Acute bacterial skin and skin-structure infection Therapies: DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others
Acute bacterial skin and skin-structure infection Therapeutic Assessment: Acute bacterial skin and skin-structure infection current marketed and Acute bacterial skin and skin-structure infection emerging therapies
Acute bacterial skin and skin-structure infection Market Dynamics: Acute bacterial skin and skin-structure infection market drivers and Acute bacterial skin and skin-structure infection market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute bacterial skin and skin-structure infection Unmet Needs, KOL's views, Analyst's views, Acute bacterial skin and skin-structure infection Market Access and Reimbursement
To know what's more in our Acute bacterial skin and skin-structure infection report, visit https://www.Delveinsight.Com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?Utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Acute bacterial skin and skin-structure infection Market Report:
Acute bacterial skin and skin-structure infection market report covers a descriptive overview and comprehensive insight of the Acute bacterial skin and skin-structure infection Epidemiology and Acute bacterial skin and skin-structure infection market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute bacterial skin and skin-structure infection market report provides insights into the current and emerging therapies.
The Acute bacterial skin and skin-structure infection market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute bacterial skin and skin-structure infection market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute bacterial skin and skin-structure infection market.
Got queries? Click here to know more about the Acute bacterial skin and skin-structure infection market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute bacterial skin and skin-structure infection Patient Share (%) Overview at a Glance
5. Acute bacterial skin and skin-structure infection Market Overview at a Glance
6. Acute bacterial skin and skin-structure infection Disease Background and Overview
7. Acute bacterial skin and skin-structure infection Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute bacterial skin and skin-structure infection
9. Acute bacterial skin and skin-structure infection Current Treatment and Medical Practices
10. Unmet Needs
11. Acute bacterial skin and skin-structure infection Emerging Therapies
12. Acute bacterial skin and skin-structure infection Market Outlook
13. Country-Wise Acute bacterial skin and skin-structure infection Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute bacterial skin and skin-structure infection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Acute bacterial skin and skin-structure infection Market Outlook 2034
Related Reports:
Acute bacterial skin and skin-structure infection Pipeline Insights, DelveInsight
"Acute bacterial skin and skin-structure infection Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute bacterial skin and skin-structure infection market. A detailed picture of the Acute bacterial skin and skin-structure infection pipeline landscape is provided, which includes the disease overview and Acute bacterial skin and skin-structure infection treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name:DelveInsight Business Research LLPContact Person: Kritika RehaniEmail:Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite:https://www.Delveinsight.Com/
Press Release Distributed by ABNewswire.ComTo view the original version on ABNewswire visit: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market: Insights into Epidemiology, Treatments, and Key CompaniesMicuRx, Basilea Pharmaceuticals, AbbVie, Cubist Pharmaceuticals LLC, Nabr
New Bacteria Discovered In Flies Could Sicken Humans
A new species of bacteria has come to light in Brazil. It's genetically similar to two other disease-causing bacteria from the Andes, which are known to infect humans through sand fly bites.
According to a study published this summer in the journal Acta Tropica, researchers have discovered a new bacteria species in phlebotomine insects (sand flies) in the Amazon National Park in Brazil's state of Pará. Its DNA is similar to that of two Andean bacteria in Peru, Bartonella bacilliformis and Bartonella ancashensis. While these cause Carrión's disease and are also transmitted by phlebotomine sand flies, there is no evidence in Brazil of the new species causing disease. Nevertheless, the researchers argue that more research is needed.
In the same genus as disease-causing bacteria"The discovery of Bartonella species in phlebotomine sand flies here in Brazil may indicate that B. Bacilliformis and B. Ancashensis, which cause Carrión's disease or Peruvian wart, can adapt to non-Andean species and be transmitted in areas outside the Andes," Eunice Aparecida Bianchi Galati, a co-author of the study and an associate professor in the Department of Epidemiology of the Public Health School of the University of São Paulo, said in a statement by the São Paulo Research Foundation.
Galati adds that "this isn't too much of an extrapolation" because two species in Peru that can transmit B. Bacilliformis are similar to two Brazilian species.
The newly discovered bacterial species is also a member of the genus Bartonella. Bartonellosis is a group of diseases, including Carrión's disease, caused by Bartonella bacteria, which can be transmitted in various ways, such as fleas and lice in addition to sand flies. Among other symptoms, the disease usually manifests as a drawn-out infection in both humans and animals and can be problematic for immunocompromised patients. What's more, the pathogen can exist unnoticed in an individual for significant periods of time.
"Bartonellosis is a neglected disease. The disease best known to health professionals is cat scratch disease, caused by Bartonella henselae," explained Marcos Rogério André, a co-author of the study and a veterinary doctor at the Universidade Estadual Paulista. "It's important to understand the real prevalence of these diseases, especially in isolated regions with low human development indices, where populations don't have easy access to health services."
Doctors and researchers, unite!André and his colleagues studied Bartonella DNA in 297 specimens of female sand flies from near the banks of the Uruá and Tracoá rivers in Pará's Amazon National Park, which hosts many visitors.
"We're detecting a strain here in Brazil that's never been described and is very similar to two species of the Bartonella genus that cause disease in Andean countries. Despite this similarity, we don't yet have information on whether it can cause disease with distinct symptoms. That's why we need to study them further," André explained. He suggests that doctors and researchers should work together to investigate Bartonella bacteria in patients with unexplainable fevers.
"Could people with fever who are often sent home and who have repeated episodes of fever be infected with this pathogen?" he wondered. "Could patients with Leishmania also be co-infected with this new species of Bartonella?"
Here's to hoping the new microbe doesn't take from the bad side of the family.
Five Deaths Reported Amid Bacterial Infection Outbreak In Major City
NEWYou can now listen to Fox News articles!
A total of five people have now died amid an outbreak of bacterial pneumonia, which has infected dozens of people in New York City, according to health officials.
As of Aug. 19, there have been 108 confirmed cases of Legionnaires' disease, a type of pneumonia caused by the bacteria Legionella.
Fourteen people are currently hospitalized, according to NYC Health.
DEATHS REPORTED AFTER LEGIONNAIRES' DISEASE OUTBREAK AT SENIOR LIVING FACILITY
The cluster of cases is concentrated in Central Harlem and bordering communities (zip codes 10027, 10030, 10035, 10037 and 10039).
"Anyone in these zip codes with flu-like symptoms should contact a healthcare provider as soon as possible," said Acting Health Commissioner Dr. Michelle Morse in the health department's previous alert.
A total of 58 people in Central Harlem have been diagnosed with Legionnaires' disease, a bacterial pneumonia. (iStock)
Legionnaires' is usually found in lakes, streams and other freshwater environments.
However, it can grow and spread indoors via shower heads, sink faucets, hot tubs, water features/fountains, plumbing systems and other water systems where conditions are favorable for the Legionella bacteria to grow, according to the Centers for Disease Control and Prevention (CDC).
HIGHLY CONTAGIOUS DISEASE SURGES IN SOME US STATES AMID REPORT OF POSSIBLE FATAL CASE
When people swallow or breathe in droplets of water that contain Legionella, they can potentially become ill with Legionnaires' disease.
The disease is not typically spread from person to person, per the CDC.
Legionnaires' disease is caused by the bacteria Legionella, which can cause flu-like symptoms and respiratory problems. (iStock)
In the case of the New York City outbreak, the health department directed the state to perform remediation for 11 cooling towers that tested positive for the bacteria.
"Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin," Morse added.
Symptoms and riskSymptoms of Legionnaires' disease usually show up between two and 14 days after exposure.
The condition usually causes flu-like symptoms, including cough, chills, muscle aches, fever or difficulty breathing.
Some patients may also experience nausea, diarrhea and confusion, the CDC noted.
When people swallow or breathe in droplets of water that contain Legionella, they can potentially become ill with Legionnaires' disease. (iStock)
"The nature of the symptoms is not necessarily what differentiates Legionella from other causes, but history of exposure from 'human-made reservoirs,' though this may be hard to discern early on in infection and/or in an outbreak," said Goodyear.
Those who have any of these symptoms should seek medical attention immediately, the CDC advises.
CLICK HERE TO GET THE FOX NEWS APP
Groups at highest risk include smokers, people 50 and older, those with chronic lung disease and people who are immunocompromised, according to health officials.
"Other risk factors include advancing age, cardiovascular disease, obesity and compromised immune systems," Dr. Nathan Goodyear, an integrative medicine physician at the Williams Cancer Institute in California, previously told Fox News Digital.
Around 10% of people who contract Legionnaires' disease will die from complications.
Diagnosis of Legionnaires' disease is made via chest X-ray, urine test and lab analysis of a phlegm sample.
Most people with the disease will recover with a course of antibiotics.
In some patients, however, serious illness can lead to lung failure or death, per the CDC.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Around 10% of people who contract Legionnaires' disease will die from those complications — and the mortality risk rises to 25% for those who get Legionnaires' while staying in a healthcare facility.
"Treatment needs to be early and aggressive," Goodyear told Fox News Digital. "Legionella infection is an intracellular infection that requires antibiotic treatment."
Legionella bacteria can grow and spread indoors via shower heads, sink faucets, hot tubs, water features/fountains, plumbing systems and other water systems. (iStock)
Antibiotics that are appropriate for Legionella infection include Levofloxacin and Azithromycin.
"Therapy can be prescribed orally in healthy individuals … but intravenous antibiotics often prove to be the initial option for treatment secondary to the pathogenicity of the disease," Goodyear said.
Prevention strategiesCurrently, there are no vaccines for Legionnaires' disease.
The best strategy to prevent infection is to reduce the growth and spread of the Legionella bacteria.
For more Health articles, visit www.Foxnews.Com/health
The CDC recommends that building owners and managers use a water management program to reduce the risk.
To prevent serious illness from Legionnaires', Goodyear recommends that all smokers kick the habit, and also emphasizes the need to "aggressively support" chronic pulmonary disease.
Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.Rudy@fox.Com.
Comments
Post a Comment